The medical device contract development and manufacturing organization reported a net profit of $48.6 million, or $1.38 per share, a significant increase from the $32.7 million recorded in the same period last year. When stripping out one-time items, Integer reported adjusted earnings of $1.76 per share, beating the $1.70 per share consensus expected by analysts polled by FactSet. Quarterly revenue rose 5% to $472.1 million, also clearing the $462.7 million target anticipated by the market.

Growth Projections and Full-Year Guidance

Management provided an optimistic roadmap for the current fiscal year, projecting total sales between $1.83 billion and $1.88 billion. The midpoint of this range sits comfortably above the $1.84 billion analyst estimate. The company expects adjusted earnings for the year to land between $6.29 and $6.78 per share, the majority of which sits ahead of the $6.30 per share floor set by Wall Street projections.

Despite the 3.8% jump to $89.51 on Thursday morning, Integer continues to work through a volatile period for its valuation. The stock has retreated 38% over the past year, though the latest earnings beat suggests a recovery in operational momentum. The company’s ability to outpace revenue expectations reflects a stabilizing environment for medical device outsourcing and supply chain management.